36. 表皮水疱症
[臨床試験数:147,薬物数:170(DrugBank:40),標的遺伝子数:32,標的パスウェイ数:113

Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04177498
(ClinicalTrials.gov)
January 1, 20217/11/2019Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCCA Pilot, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell CarcinomaRecessive Dystrophic Epidermolysis BullosaDrug: Rigosertib Sodium;Other: Quality-of-Life AssessmentThomas Jefferson UniversityOnconova Therapeutics, Inc.Not yet recruiting18 Years79 YearsAll6Early Phase 1United States